跳至主要内容
临床试验/CTRI/2023/11/060303
CTRI/2023/11/060303已完成1 期

Evaluation of dermatological safety of investigational products by 24hrs patch test under complete occlusion on healthy human subjects of varied skin types.

ITC Life Sciences & Technology Centre1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年12月6日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
To evaluate the dermatological safety of the

研究概览

简要总结

It is a primary irritation patch test clinical study under dermatological control. A patch test under occlusion is carried out using the occlusive chambers prefixed to a micropore tape followed by an assessment. This patch will then be applied on the test site i.e., between your scapulae and waist on your upper back. The patch will be kept for 24 hours. After which the patch will be removed and the first observation will be made at 30 minutes of patch removal (0 hr. reading). The further observations will be at 24 hrs, and 1 week post patch removal. The dermatological assessment will be done at each visit. Study would be conducted over a period of 9 days and would include a total of 4-5 visits.

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Subjects with Fitzpatrick skin type III to V.
  • Subjects in good health condition as per the medical screening criteria with no disease state or physical condition that the Investigator believes could interfere with the interpretation of the data.
  • Subject able to read, understand and sign an appropriate informed consent form indicating her willingness to participate.
  • Subjects willing to give a voluntary written informed consent.
  • Subjects willing to maintain the patch test in position for 24 hours.
  • Subject having not participated in a similar investigation in the past two weeks.
  • Subjects willing to come for regular follow up visits.

排除标准

  • Subjects with infection, allergy on the tested area.
  • Subjects with skin allergy, antecedents or atopic subjects.
  • Athletes and subjects with history of excessive sweating.
  • Subjects with cutaneous disease which may influence the study result.
  • Subjects on oral corticosteroid.
  • Subjects participating in any other cosmetic or therapeutic trial.
  • Subjects who are currently pregnant or lactating or planning to become pregnant in the period of study.
  • Subjects with any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.
  • More than one subject selected/ participating from one family/ household.
  • Subjects working with MSCR.

结局指标

主要结局

To evaluate the dermatological safety of the

时间窗: Approximately 9 days for each subject

investigational products on healthy human

时间窗: Approximately 9 days for each subject

subjects

时间窗: Approximately 9 days for each subject

次要结局

  • NA(NA)

研究者

发起方
ITC Life Sciences & Technology Centre
申办方类型
Other [FMCG (Fast moving Consumer Goods)]
责任方
Principal Investigator
主要研究者

Dr Navya Annam

MS Clinical Research Pvt Ltd

研究点 (1)

Loading locations...

相似试验